Rankings
▼
Calendar
JANX Q1 2024 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
JANX
Janux Therapeutics, Inc.
$852M
Q1 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1M
-38.9% YoY
Gross Profit
$720,000
57.5% margin
Operating Income
-$20M
-1610.3% margin
Net Income
-$15M
-1178.9% margin
EPS (Diluted)
$-0.30
QoQ Revenue Growth
-49.1%
Cash Flow
Operating Cash Flow
-$15M
Free Cash Flow
-$15M
Stock-Based Comp.
$6M
Balance Sheet
Total Assets
$689M
Total Liabilities
$33M
Stockholders' Equity
$656M
Cash & Equivalents
$213M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1M
$2M
-38.9%
Gross Profit
$720,000
-$14M
+105.2%
Operating Income
-$20M
-$20M
+0.6%
Net Income
-$15M
-$17M
+15.5%
← FY 2024
All Quarters
Q2 2024 →